Essex Woodlands Management Inc. Has $15.45 Million Position in Eyepoint Pharmaceuticals, Inc. $EYPT

Essex Woodlands Management Inc. reduced its holdings in Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 7.3% during the third quarter, Holdings Channel reports. The firm owned 1,084,857 shares of the company’s stock after selling 85,000 shares during the period. Eyepoint Pharmaceuticals makes up 5.0% of Essex Woodlands Management Inc.’s portfolio, making the stock its 3rd largest holding. Essex Woodlands Management Inc.’s holdings in Eyepoint Pharmaceuticals were worth $15,448,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Nisa Investment Advisors LLC boosted its holdings in Eyepoint Pharmaceuticals by 1,636.5% during the second quarter. Nisa Investment Advisors LLC now owns 2,900 shares of the company’s stock worth $27,000 after buying an additional 2,733 shares in the last quarter. State of Alaska Department of Revenue bought a new position in shares of Eyepoint Pharmaceuticals in the third quarter valued at $50,000. Tower Research Capital LLC TRC lifted its position in shares of Eyepoint Pharmaceuticals by 218.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company’s stock valued at $82,000 after acquiring an additional 5,967 shares during the last quarter. Raymond James Financial Inc. lifted its position in shares of Eyepoint Pharmaceuticals by 11.0% during the 2nd quarter. Raymond James Financial Inc. now owns 11,900 shares of the company’s stock valued at $112,000 after acquiring an additional 1,177 shares during the last quarter. Finally, Inceptionr LLC bought a new stake in shares of Eyepoint Pharmaceuticals during the 2nd quarter worth $131,000. 99.41% of the stock is owned by institutional investors and hedge funds.

Eyepoint Pharmaceuticals Stock Performance

EYPT stock opened at $17.86 on Friday. The firm has a 50 day simple moving average of $15.77 and a 200 day simple moving average of $14.08. Eyepoint Pharmaceuticals, Inc. has a 52 week low of $3.91 and a 52 week high of $19.11. The stock has a market cap of $1.48 billion, a P/E ratio of -5.97 and a beta of 1.76.

Insider Activity

In other news, insider Ramiro Ribeiro sold 42,544 shares of the business’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $17.10, for a total transaction of $727,502.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 4.46% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Cantor Fitzgerald raised Eyepoint Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, November 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a report on Thursday, January 22nd. Royal Bank Of Canada raised their target price on shares of Eyepoint Pharmaceuticals from $28.00 to $39.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Finally, TD Cowen raised shares of Eyepoint Pharmaceuticals to a “strong-buy” rating in a research report on Friday, December 19th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $29.25.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.